A RANDOMIZED ACTIVE CONTROLLED CLINICAL STUDY TO EVALUATE EFFICACY AND SAFETY OF RESVERATROL AS AN ADJUVANT THERAPY IN PATIENTS WITH HYPERTENSION
| Autor: | Vyas Bhavin, Kulkarni Pranesh, Rakesh Ojha |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Pharmacology medicine.medical_specialty business.industry medicine.medical_treatment Urology Pharmaceutical Science Resveratrol Essential hypertension medicine.disease 03 medical and health sciences chemistry.chemical_compound 030104 developmental biology Blood pressure chemistry Adjuvant therapy Medicine Pharmacology (medical) In patient Telmisartan business Adverse effect Adjuvant medicine.drug |
| Zdroj: | Asian Journal of Pharmaceutical and Clinical Research. 10:376 |
| ISSN: | 2455-3891 0974-2441 |
| Popis: | Objectives: No long-term clinical efficacy and safety study of resveratrol as adjuvant therapy along with gold standard therapy has been conductedin patients with essential hypertension. The aim of this study was to investigate the efficacy and safety of resveratrol as an adjuvant therapy in newlydiagnosed hypertensive patients.Methods: In this randomized active-controlled study, hypertensive patients (male/female) of 20-65 years aged were randomized (1:1) to receivetelmisartan 20 mg or telmisartan 20 mg plus resveratrol 1 g daily for 12 months. Efficacy variables included a change in systolic and diastolic bloodpressure (DBP) from baseline and were followed up for every 3 months. Treatment-emergent adverse events were assessed.Results: A total of 60 hypertensive patients were analyzed (telmisartan [n=30] and telmisartan plus resveratrol [n=30]). Resveratrol as an adjuvantwith telmisartan significantly reduced in systolic (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|